No Match Found
As the medtech industry regains its footing post-pandemic, leaders have many options in preparing for future challenges and creating shareholder value.
After a decade of strong shareholder returns, medtech companies were particularly impacted by the COVID-19 pandemic. Reduced procedure volumes, supply chain disruption, the great resignation and turbulent capital markets all served to undermine a fundamentally solid industry.
But there are encouraging signs the industry is strongly rebounding.
Just because the medtech industry is poised for a rebound, that doesn’t mean it’s time to relax.
The positive outlook comes with increased investor expectations and challenges from new entrants and disruptors. To help your medtech company build resilience and deliver durable growth, now is the time to reevaluate five key areas of your operations: commercial strategy, product development, supply chain, workplace culture and business development.
To help your medtech company build resilience and deliver durable growth, now is the time to reevaluate five key areas of your operations.
Principal, Deals, PwC US
Management Consulting Partner, PwC US
Partner, Strategy& US
Principal, Workforce Transformation, Pharma & Life Sciences, PwC US